1: Kim S, Lee JM. A Case of Pranlukast-Induced Anaphylactic Shock. Allergy Asthma 
Immunol Res. 2016 May;8(3):276-8. doi: 10.4168/aair.2016.8.3.276. PubMed PMID: 
26922938; PubMed Central PMCID: PMC4773216.

2: Harada S, Harada N, Itoigawa Y, Katsura Y, Kasuga F, Ishimori A, Makino F, Ito 
J, Atsuta R, Takahashi K. Evaluation of switching low-dose inhaled corticosteroid 
to pranlukast for step-down therapy in well-controlled patients with mild 
persistent asthma. J Asthma. 2016 Mar;53(2):207-12. doi: 
10.3109/02770903.2015.1087556. Epub 2015 Nov 2. PubMed PMID: 26325232.

3: Hao Y, Wang L, Li J, Liu N, Feng J, Zhao M, Zhang X. Enhancement of 
Solubility, Transport Across Madin-Darby Canine Kidney Monolayers and Oral 
Absorption of Pranlukast Through Preparation of a Pranlukast-Phospholipid 
Complex. J Biomed Nanotechnol. 2015 Mar;11(3):469-77. PubMed PMID: 26307829.

4: Furuta H, Mori S, Yoshihashi Y, Yonemochi E, Uekusa H, Sugano K, Terada K. 
Physicochemical and crystal structure analysis of pranlukast pseudo-polymorphs I: 
anhydrates and hydrate. J Pharm Biomed Anal. 2015 Mar 25;107:11-6. doi: 
10.1016/j.jpba.2014.12.007. Epub 2014 Dec 13. PubMed PMID: 25562844.

5: Ha ES, Baek IH, Yoo JW, Jung Y, Kim MS. Improving dissolution and oral 
bioavailability of pranlukast hemihydrate by particle surface modification with 
surfactants and homogenization. Drug Des Devel Ther. 2015 Jun 24;9:3257-66. doi: 
10.2147/DDDT.S87738. eCollection 2015. PubMed PMID: 26150699; PubMed Central 
PMCID: PMC4484661.

6: Ebisawa M, Terada A, Sato K, Kurosaka F, Kondo N, Sugizaki C, Morikawa A, 
Nishima S, Urashima M. Intermittent and episode-driven use of pranlukast to 
reduce the frequency of wheezing in atopic children: a randomized, double-blind, 
placebo-controlled trial. World Allergy Organ J. 2015 Apr 2;8(1):11. doi: 
10.1186/s40413-015-0062-3. eCollection 2015. PubMed PMID: 25866598; PubMed 
Central PMCID: PMC4382836.

7: Furuta H, Mori S, Yoshihashi Y, Yonemochi E, Uekusa H, Sugano K, Terada K. 
Physicochemical and crystal structure analysis of pranlukast pseudo-polymorphs 
II: Solvate and cocrystal. J Pharm Biomed Anal. 2015;111:44-50. doi: 
10.1016/j.jpba.2015.03.008. Epub 2015 Mar 17. PubMed PMID: 25854856.

8: Baek IH, Kim JS, Ha ES, Choo GH, Cho W, Hwang SJ, Kim MS. Dissolution and oral 
absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl 
cellulose. Int J Biol Macromol. 2014 Jun;67:53-7. doi: 
10.1016/j.ijbiomac.2014.03.006. Epub 2014 Mar 13. PubMed PMID: 24631786.

9: Tang SS, Ji MJ, Chen L, Hu M, Long Y, Li YQ, Miao MX, Li JC, Li N, Ji H, Chen 
XJ, Hong H. Protective effect of pranlukast on Aβ₁₋₄₂-induced cognitive deficits 
associated with downregulation of cysteinyl leukotriene receptor 1. Int J 
Neuropsychopharmacol. 2014 Apr;17(4):581-92. doi: 10.1017/S1461145713001314. Epub 
2013 Nov 11. PubMed PMID: 24229499.

10: Hara H, Sugahara K, Hashimoto M, Mikuriya T, Tahara S, Yamashita H. 
Effectiveness of the leukotriene receptor antagonist pranlukast hydrate for the 
treatment of sleep disorder in patients with perennial allergic rhinitis. Acta 
Otolaryngol. 2014 Mar;134(3):307-13. doi: 10.3109/00016489.2013.861926. Epub 2014 
Jan 27. PubMed PMID: 24460152.

11: Sugihara H, Matsui Y, Takeuchi H, Wilding I, Connor A, Abe K, Nishiura A. 
Development of a gastric retentive system as a sustained-release formulation of 
pranlukast hydrate and its subsequent in vivo verification in human studies. Eur 
J Pharm Sci. 2014 Mar 12;53:62-8. doi: 10.1016/j.ejps.2013.11.018. Epub 2013 Dec 
4. PubMed PMID: 24316098.

12: Pathomthongtaweechai N, Soodvilai S, Chatsudthipong V, Muanprasat C. 
Pranlukast inhibits renal epithelial cyst progression via activation of 
AMP-activated protein kinase. Eur J Pharmacol. 2014 Feb 5;724:67-76. doi: 
10.1016/j.ejphar.2013.12.013. Epub 2013 Dec 17. PubMed PMID: 24360935.

13: Matsuse H, Kohno S. Leukotriene receptor antagonists pranlukast and 
montelukast for treating asthma. Expert Opin Pharmacother. 2014 Feb;15(3):353-63. 
doi: 10.1517/14656566.2014.872241. Epub 2013 Dec 19. Review. PubMed PMID: 
24350802.

14: Takahashi Y, Imai K, Ikeda H, Kubota Y, Yamazaki E, Susa F. Open study of 
pranlukast add-on therapy in intractable partial epilepsy. Brain Dev. 2013 
Mar;35(3):236-44. doi: 10.1016/j.braindev.2012.04.001. Epub 2012 May 7. PubMed 
PMID: 22571867.

15: Baek MK, Lee JH, Cho YH, Kim HH, Lee GW. Self-microemulsifying drug-delivery 
system for improved oral bioavailability of pranlukast hemihydrate: preparation 
and evaluation. Int J Nanomedicine. 2013;8:167-76. doi: 10.2147/IJN.S37338. Epub 
2013 Jan 7. PubMed PMID: 23326192; PubMed Central PMCID: PMC3544354.

16: Gotoh M, Okubo K, Hashiguchi K, Wakabayashi K, Kanzaki S, Tanaka N, Fujioka 
M, Kawashima K, Suematsu K, Sasaki K, Iwasaki M, Yamamotoya H. Noninvasive 
biological evaluation of response to pranlukast treatment in pediatric patients 
with Japanese cedar pollinosis. Allergy Asthma Proc. 2012 Nov-Dec;33(6):459-66. 
doi: 10.2500/aap.2012.33.3615. PubMed PMID: 23394502.

17: Wang L, Hao Y, Liu N, Ma M, Yin Z, Zhang X. Enhance the dissolution rate and 
oral bioavailability of pranlukast by preparing nanosuspensions with 
high-pressure homogenizing method. Drug Dev Ind Pharm. 2012 Nov;38(11):1381-9. 
Epub 2012 Feb 3. PubMed PMID: 22300415.

18: Matsuse H, Fukahori S, Tsuchida T, Kawano T, Tomari S, Matsuo N, Nishino T, 
Fukushima C, Kohno S. Effects of a short course of pranlukast combined with 
systemic corticosteroid on acute asthma exacerbation induced by upper respiratory 
tract infection. J Asthma. 2012 Aug;49(6):637-41. doi: 
10.3109/02770903.2012.685539. Epub 2012 Jun 29. PubMed PMID: 22746973.

19: Yasui H, Fujisawa T, Inui N, Kato M, Hashimoto D, Enomoto N, Nakamura Y, 
Shirai T, Suda T, Nakamura H, Chida K. Impact of add-on pranlukast in stable 
asthma; the additive effect on peripheral airway inflammation. Respir Med. 2012 
Apr;106(4):508-14. doi: 10.1016/j.rmed.2011.12.014. Epub 2012 Jan 21. PubMed 
PMID: 22265857.

20: Shimbori C, Shiota N, Okunishi H. Pranlukast, a cysteinyl leukotriene type 1 
receptor antagonist, attenuates the progression but not the onset of 
silica-induced pulmonary fibrosis in mice. Int Arch Allergy Immunol. 
2012;158(3):241-51. doi: 10.1159/000331439. Epub 2012 Feb 27. PubMed PMID: 
22378144.